Evotec SE
NASDAQ:EVODrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $518.56M
- Beta
- 1.30
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$1.09
Volume 0.04M
Average 0.08M
EVO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Evotec SENASDAQ: EVO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of €159.22M fell 20.4% year over year, behind the -5.5% change in trailing-twelve-month revenue. Sequentially, it fell 36.5% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of €604.5M (-20.2%) for the fiscal year ending Dec 2026, a slowdown from the -5.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- €159.22M-36.5% QoQ
- Last fiscal yearDec 2025
- €757.26M-5.0% YoY
- LTMMar 2026
- €745.24M-5.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -20.4% | -16.2% | +4.2 pp |
| 1 year | -5.0% | -20.2% | -15.2 pp |
| 3-year CAGR | +0.3% | -0.2% | -0.5 pp |
| 5-year CAGR | +3.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
EUR · from the income statement
- Latest · FY2025
- 757.26M EUR
- Year-over-year change
- -5.0%
- 4-year CAGR
- +5.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 757.26M | -5.0% |
| FY2024 | 2024-12-31 | 796.97M | +2.0% |
| FY2023 | 2023-12-31 | 781.43M | +4.0% |
| FY2022 | 2022-12-31 | 751.45M | +21.6% |
| FY2021 | 2021-12-31 | 618.03M | — |
Revenue vs competitors
How EVO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -5.5% is the lowest of 9, against a peer median of +4.6%.
- Over three fiscal years its annual growth of +0.3% compares with a peer median of +9.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.51B USD | -1.5% | +1.7% | |
| LTM Feb 2026 | $1.18B USD | +3.1% | +12.5% | |
| LTM Mar 2026 | €745.24M EUR | -5.5% | +0.3% | |
| LTM Mar 2026 | $734.86M USD | +4.6% | +2.9% | |
| LTM Mar 2026 | $674.41M USD | +8.5% | +6.8% | |
| LTM Sep 2026 | $621.7M USD | +4.7% | -2.2% | |
| LTM Mar 2026 | $559.42M USD | -4.5% | +91.9% | |
| LTM Sep 2026 | $269.2M USD | +4.8% | +12.2% | |
| LTM Mar 2026 | $268.68M USD | +26.2% | +45.4% | |
| LTM Sep 2026 | $90.49M USD | — | — | |
| LTM Sep 2026 | €0 EUR | — | — | |
| Peer median (excluding EVO) | — | +4.6% | +9.5% | |
Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 618.03M | 751.45M | 781.43M | 796.97M | 757.26M |
| Cost of Revenue | 466.49M | 577.38M | 606.38M | 682.09M | 694.6M |
| Gross Profit | 151.54M | 174.07M | 175.05M | 114.88M | 62.66M |
| Gross Margin | 24.5% | 23.2% | 22.4% | 14.4% | 8.3% |
| Research & Development | 65.7M | 76.64M | 68.53M | 50.86M | 74.33M |
| Selling, General & Admin | 105.45M | 156.19M | 169.61M | 188.2M | 123.65M |
| Operating Expenses | 110.55M | 153.22M | 222.56M | 257.4M | 197.97M |
| Depreciation & Amortization | 70.4M | 83.2M | 92.98M | 101.62M | 95.55M |
| EBITDA | 316.63M | (57.61M) | 24.13M | (80.66M) | (13.89M) |
| EBITDA Margin | 51.2% | -7.7% | 3.1% | -10.1% | -1.8% |
| Operating Income | 41M | 20.85M | (47.51M) | (142.52M) | (135.31M) |
| Operating Margin | 6.6% | 2.8% | -6.1% | -17.9% | -17.9% |
| Interest Income | 2.27M | 8.34M | 9.26M | 2.44M | 4.25M |
| Interest Expense | 9.25M | 13.15M | 11.74M | 11.7M | 13.87M |
| Other Income / Expenses | 195.98M | (174.81M) | (33.09M) | (51.46M) | 12M |
| Income Before Tax | 236.98M | (153.96M) | (80.59M) | (193.98M) | (123.31M) |
| Pre-Tax Margin | 38.3% | -20.5% | -10.3% | -24.3% | -16.3% |
| Income Tax Expense | 21.47M | 21.7M | 3.32M | 2.1M | (23.88M) |
| Net Income | 215.51M | (175.66M) | (83.91M) | (196.08M) | (99.43M) |
| Net Margin | 34.9% | -23.4% | -10.7% | -24.6% | -13.1% |
| EPS (Basic) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| EPS (Diluted) | 0.65 | (0.49) | (0.23) | (0.56) | (0.28) |
| Weighted Avg Shares | 332.81M | 353.35M | 353.87M | 353.29M | 355.16M |
| Weighted Avg Shares (Diluted) | 332.81M | 353.41M | 353.87M | 354.59M | 355.16M |
Evotec SE
NASDAQ:EVO
Intrinsic Alpha fair value
Locked
Current Price
$1.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.